You are

part of a clinical trial team evaluating two experimental Alzheimer’s disease

treatments:

• Drug A:

  A

  monoclonal antibody that targets amyloid-beta oligomers

• Drug B:

  A

  small molecule that inhibits tau hyperphosphorylation

Critically

evaluate which drug is more likely to have a greater impact on improving

cognitive function in the early stages of Alzheimer’s disease.

In your answer:

• Explain the role of amyloid-beta and tau in

  disease progression

• Evaluate the likely effectiveness of targeting

  each in early-stage patients

• Make and justify a recommendation on which

  should progress to Phase III trials